Ambalal Sarabhai Enterprises Ltd Share Price

Trading - Medium / SmallNSE
₹47.74
+1.42+3.07% (1D)
As on 21 Aug 2026 at 05:57
As of 21 Aug 2026 at 05:57, Ambalal Sarabhai Enterprises Ltd is trading at ₹47.74, with a market cap of ₹365.08 crore. At a P/E of 88.22 and a dividend yield of 0.00%, it is a small-cap stock in the Pharmaceuticals sector.

AMBALALSA Price Chart

Market Cap
₹365.08 Cr
PE Ratio
88.22
ROCE
14.69%

Ambalal Sarabhai Enterprises Ltd Performance

Ambalal Sarabhai Enterprises Ltd Fundamentals

Market Cap₹365.08 Cr
ROE18.48%
P/E Ratio (TTM)88.22
EPS (TTM)₹0.54
P/B Ratio6.14
Dividend Yield0.00%
Industry P/E92.64
Book Value₹7.76
Debt to Equity0.18
Face Value₹10

Ambalal Sarabhai Enterprises Ltd Shareholding Pattern

Promoter31.4%
Foreign Institutions0%
Mutual Funds0%
Domestic Institutions0%
Public68.6%

Ambalal Sarabhai Enterprises Ltd Financial Statements

No data for this view.

Ambalal Sarabhai Enterprises Ltd Peer Comparison

StocksLTP(₹)Market Cap(Cr)
Sun Pharmaceutical Industries Ltd
₹1,901.00
1.00(+0.05%)
4,56,113.6
Torrent Pharmaceuticals Ltd
₹4,994.90
-18.10(-0.36%)
1,89,989.9
Cipla Ltd
₹1,437.65
15.65(+1.10%)
1,16,141.0
Lupin Ltd
₹2,203.10
-21.90(-0.98%)
1,00,732.9
Dr Reddys Laboratories Ltd
₹1,181.35
11.35(+0.97%)
98,604.4

About Ambalal Sarabhai Enterprises

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses. It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments. Pharmaceuticals segment is engaged in manufacture of drugs and formulations. Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company. During the year 1998-99, the company signed agreement with B V Chiron, Netherlands for introducing their anti-cancer drugs in India. During the year 1999-2000, the company entered into an MoU for marketing of products of Oncology products of Chiron Corporation, USA. The Product Division essentially comprising of Sarabai Chemicals Products was transferred to the joint venture company, Sarabhai Piramal Pharmaceuticals Ltd. In September 2008, the company acquired the manufacturing and marketing company, namely Suvik Hitek Pvt. Ltd. The Ethical Division re-launched the products of Suvik and Sarabhai Chemicals in market. Also, the company acquired Systronics (India) Pvt Ltd. During the year 2008-09, the Oncology Division launched two new products viz. Fludagem & Xtinib. Also, the company promoted a company viz. Vovanties Laboratories Pvt Ltd, a pharmaceutical specialist with a vision to establish a state of the art manufacturing facility specializing in Novel Effervescent Drug Delivery System. During the year 2010-11, the Company had transferred and assigned as going concern, the business undertaking of Sarabhai Chemicals Bulk Drug Division to Synbiotics Ltd and Electronics Division comprising of Systronics, Teleradand SERC to Systronics (India) Ltd with effect from October 01, 2010. Sarabhai M Chemicals Ltd, a wholly owned subsidiary company started its Vitamin C coated products manufacturing since August 2019. In June 2023, Asence Pharma Pvt., Ltd. a subsidiary of the Company commenced its new oncology and synthetic API plant at Ranoli, Vadodara. The Company has scaled up operations at its oncology and synthetic API manufacturing facility at Ranoli, Vadodara in 2026. It strengthened the presence in the domestic pharmaceutical market with a focused portfolio in Oncology, Fertility, Women's Healthcare and other specialty therapeutic segments.

Parent Organisation
Founded1977
Managing DirectorMohal Kartikeya Sarabhai
NSE SymbolAMBALALSA

Ambalal Sarabhai Enterprises Ltd Resistance and Support levels

R349.26R248.19R147.54S145.40S244.75S343.6847.74

Ambalal Sarabhai Enterprises Ltd Technicals

Current Price
₹47.74 ₹1.42 (+3.07%)
Bearish
2
Bullish
10
  • 20 Day13.9%
  • 50 Day26.9%
  • 100 Day38.6%
  • 200 Day38.6%

Ambalal Sarabhai Enterprises Ltd Latest News

View More
23 MAY 2026 | Saturday
Ambalal Sarabhai Enterprises AGM scheduled
14 MAY 2026 | Thursday
Ambalal Sarabhai Enterprises schedules board meeting

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Ambalal Sarabhai Enterprises Ltd is ₹47.74 as of 21 Aug 2026 at 05:57.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now